Phosphorus-containing inhibitors of endothelin converting enzyme: effects of the electronic nature of phosphorus on inhibitor potency

Journal of Medicinal Chemistry
1993.0

Abstract

This report describes the initial findings of a program focused on the design and synthesis of inhibitors of a putative metalloprotease endothelin converting enzyme (ECE) partially purified from rabbit lung, and the investigation of the effect of the electronic nature of phosphorus on inhibitor potency. Phosphorus-containing ECE inhibitors (phosphonamide, phosphoramide, phosphonate, and phosphinate analogs of phosphoramidon) were synthesized by modifying the rhamnose moiety with simple alkyl groups. Key results: Replacing the rhamnose moiety in phosphoramidon with an ethoxy group yielded inhibitor 16 (IC50 = 109 μM), which was less potent than phosphoramidon but synthetically more attractive. Propyl phosphonamide 17 showed in vitro potency similar to phosphoramidon (IC50 identical) but was 6 times more potent in vivo. The relative potency of analogs varied with phosphorus oxidation state and substituents, where hydrophobic or steric interactions with the enzyme might have masked the electronic effects of phosphorus. Future work will aim to understand these trends and develop structure-activity relationships (SAR) for ECE inhibition.

Knowledge Graph

Similar Paper

Phosphorus-containing inhibitors of endothelin converting enzyme: effects of the electronic nature of phosphorus on inhibitor potency
Journal of Medicinal Chemistry 1993.0
Aminophosphonate endothelin converting enzyme inhibitors: potency-enhancing and selectivity-improving modifications of phosphoramidon
Bioorganic & Medicinal Chemistry Letters 1994.0
Solid phase synthesis of phosphinic acid endothelin converting enzyme inhibitors
Bioorganic & Medicinal Chemistry Letters 1996.0
Thiol and hydroxamic acid containing inhibitors of endothelin converting enzyme
Bioorganic & Medicinal Chemistry Letters 1993.0
Synthesis and biological evaluation of phosphonamidate peptide inhibitors of enkephalinase and angiotensin-converting enzyme
Journal of Medicinal Chemistry 1985.0
Design and synthesis of phosphinic acids that triply inhibit endothelin converting enzyme, angiotensin converting enzyme and neutral endopeptidase 24.11
Bioorganic & Medicinal Chemistry Letters 1996.0
Design and Synthesis of Potent, Selective Inhibitors of Endothelin-Converting Enzyme
Journal of Medicinal Chemistry 1998.0
Highly potent and selective inhibitors of endothelin converting enzyme
Bioorganic & Medicinal Chemistry Letters 1996.0
Potent and Selective Non-Peptidic Inhibitors of Endothelin-Converting Enzyme-1 with Sustained Duration of Action
Journal of Medicinal Chemistry 2000.0
(Phosphinyloxy)acyl amino acid inhibitors of angiotensin converting enzyme (ACE). 1. Discovery of (S)-1-[6-amino-2-[[hydroxy(4-phenylbutyl)phosphinyl]oxy]-1-oxohexyl]-L-proline, a novel orally active inhibitor of ACE
Journal of Medicinal Chemistry 1988.0